Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606

Phase 1CompletedNCT00434486

Wyeth is now a wholly owned subsidiary of Pfizer24 enrolled

Overview

To investigate a potential pharmacokinetic interaction between SKI-606 and ketoconazole when co-administered.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

SKI-606DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG.

Locations (1)

Unnamed facility

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Pharmacokinetics; safety and tolerability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.